Apolipoprotein Proteomic Profiling for the Prediction of Cardiovascular Death in Patients with Heart Failure.

Gilles Lemesle, Vincent Chouraki, Pascal de Groote, Annie Turkieh, Olivia Beseme, Hervé Drobecq, Philippe Amouyel, Nicolas Lamblin, Christophe Bauters, Florence Pinet

Journal: Proteomics. Clinical applications 2021;14(6):e2000035

PMID: 32918783

Full Text on Wiley View on PubMed

Abstract

PURPOSE

Risk stratification in chronic systolic heart failure (HF) is critical to identify the patients who may benefit from advanced therapies. It is aimed at identifying new biomarkers to improve prognosis evaluation and help to better understand HF physiopathology.

EXPERIMENTAL DESIGN

Prognostic evaluation is performed in 198 patients with chronic systolic HF: 99 patients who died from cardiovascular cause within three years are individually matched for age, sex, and HF etiology (ischemic vs not) with 99 patients who are alive after three years of HF evaluation. A proteomic profiling of 15 apolipoproteins (Apo) is performed: Apo-A1, -A2, -A4, -B100, -C1, -C2, -C3, -C4, -D, -E, -F, -H, -J, -L1, and -M using LC-MRM-MS.

RESULTS

In univariate analysis, the levels of Apo-B100 and -L1 are significantly lower and the levels of Apo-C1, -J, and -M are significantly higher in patients who died from cardiovascular cause as compared with patients alive. In the final statistical model, Apo-C1, Apo-J, and Apo-M improve individually the prediction of cardiovascular death. Ingenuity pathway analysis indicates these three Apo in a network associated with lipid metabolism, atherosclerosis signaling, and retinoid X receptor activation.

CONCLUSIONS

Proteomic profiling of apolipoproteins using LC-MRM-MS might be useful in clinical practice for risk stratification of HF patients.

Address: CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.; Institut Cœur Poumon, CHU Lille, USIC et Centre Hémodynamique, Lille, F-59000, France.; FACT, French Alliance for Cardiovascular Trials, Paris, F-75000, France.; CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.; CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.; Institut Cœur Poumon, CHU Lille, USIC et Centre Hémodynamique, Lille, F-59000, France.; CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.; FHU REMOD-HF.; CNRS UMR9017, Inserm U1019, CHU Lille, Institut Pasteur de Lille, Center for Infection and Immunity of Lille, Univ. Lille, Lille, 59000, France.; CHU Lille, Institut Pasteur de Lille, U1167 - RID-AGE - Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement, Univ. Lille, Inserm, Lille, F-59000, France.; Institut Cœur Poumon, CHU Lille, USIC et Centre Hémodynamique, Lille, F-59000, France.; FHU REMOD-HF.

DOI: 10.1002/prca.202000035

Link outs

Free resources

Medical:

https://medlineplus.gov/heartfailure.html

Miscellaneous:

https://assays.cancer.gov/non-CPTAC-1085

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-GZMA-1

Subscription / membership required

Full Text Sources:

https://doi.org/10.1002/prca.202000035

MeSH Terms: Apolipoprotein C-I, Apolipoproteins M, Biomarkers, Clusterin, Female, Heart Failure, Humans, Male, Middle Aged, Models, Statistical, Predictive Value of Tests, Prognosis, Proteome, Risk Factors